HK1079989A1 - Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response - Google Patents
Compositions and methods for priming monocytic dendritic cells and t cells for th-1 responseInfo
- Publication number
- HK1079989A1 HK1079989A1 HK06100064.5A HK06100064A HK1079989A1 HK 1079989 A1 HK1079989 A1 HK 1079989A1 HK 06100064 A HK06100064 A HK 06100064A HK 1079989 A1 HK1079989 A1 HK 1079989A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cells
- compositions
- response
- methods
- monocytic dendritic
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000037452 priming Effects 0.000 title 1
- 230000004044 response Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31759201P | 2001-09-06 | 2001-09-06 | |
PCT/US2002/028620 WO2003022215A2 (en) | 2001-09-06 | 2002-09-06 | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1079989A1 true HK1079989A1 (en) | 2006-04-21 |
Family
ID=32654226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06100064.5A HK1079989A1 (en) | 2001-09-06 | 2006-01-04 | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
Country Status (18)
Country | Link |
---|---|
US (2) | US20050059151A1 (xx) |
EP (3) | EP2322603B1 (xx) |
JP (3) | JP2005505270A (xx) |
KR (3) | KR20110081341A (xx) |
CN (2) | CN1636229B (xx) |
AU (1) | AU2008221592B2 (xx) |
BR (1) | BRPI0212545B8 (xx) |
CA (1) | CA2459713C (xx) |
DK (2) | DK1441591T3 (xx) |
ES (2) | ES2598109T3 (xx) |
HK (1) | HK1079989A1 (xx) |
IL (3) | IL160720A0 (xx) |
MX (1) | MXPA04002147A (xx) |
NO (2) | NO338147B1 (xx) |
NZ (1) | NZ531530A (xx) |
PL (1) | PL372098A1 (xx) |
PT (2) | PT1441591T (xx) |
WO (1) | WO2003022215A2 (xx) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
US20040057935A1 (en) * | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
RU2348418C2 (ru) * | 2002-12-06 | 2009-03-10 | Норсуэст Байотерапьютикс, Инк. | Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей |
PL209998B1 (pl) * | 2003-02-27 | 2011-11-30 | Northwest Biotherapeutics Inc | Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne |
EP1484064A1 (en) | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
WO2005037995A2 (en) * | 2003-10-06 | 2005-04-28 | Cedars-Sinai Medical Center | Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy |
WO2005043155A1 (en) * | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
US20070269414A1 (en) * | 2003-11-04 | 2007-11-22 | Shinji Okano | Method for Producing Gene Transferred Denritic Cells |
WO2006001122A1 (ja) | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
CN101336291A (zh) * | 2005-12-08 | 2008-12-31 | 西北生物治疗药物公司 | 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法 |
EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
US8097256B2 (en) | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
PL2328923T3 (pl) | 2008-09-02 | 2016-06-30 | Cedars Sinai Medical Center | Epitopy CD133 |
PT2427485T (pt) * | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Epitopos cd133 |
AU2013215116A1 (en) * | 2012-02-02 | 2014-08-21 | Caladrius Biosciences | Pluripotent germ layer origin antigen presenting cancer vaccine |
EP2857498B1 (en) * | 2012-05-31 | 2018-04-25 | JW Creagene Inc. | Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same |
AU2020203845C1 (en) * | 2012-09-06 | 2022-08-11 | Orbis Health Solutions, Llc | Tumor lysate loaded particles |
US9744193B2 (en) * | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
WO2014093454A1 (en) | 2012-12-12 | 2014-06-19 | Orbis Health Solutions, Llc | Compositions and methods for tissue regeneration |
US10137182B2 (en) | 2013-02-14 | 2018-11-27 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
CN112891522A (zh) * | 2013-09-05 | 2021-06-04 | 奥比思健康解决方案有限责任公司 | 装载了肿瘤裂解物的微粒 |
EP3113759B1 (en) | 2014-03-05 | 2021-05-12 | Orbis Health Solutions LLC | Vaccine delivery systems using yeast cell wall particles |
US11669090B2 (en) | 2014-05-20 | 2023-06-06 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation feature monitoring and evaluation of effectiveness |
US10354330B1 (en) | 2014-05-20 | 2019-07-16 | State Farm Mutual Automobile Insurance Company | Autonomous feature use monitoring and insurance pricing |
US10599155B1 (en) | 2014-05-20 | 2020-03-24 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation feature monitoring and evaluation of effectiveness |
US9972054B1 (en) | 2014-05-20 | 2018-05-15 | State Farm Mutual Automobile Insurance Company | Accident fault determination for autonomous vehicles |
US10373259B1 (en) | 2014-05-20 | 2019-08-06 | State Farm Mutual Automobile Insurance Company | Fully autonomous vehicle insurance pricing |
US10475127B1 (en) | 2014-07-21 | 2019-11-12 | State Farm Mutual Automobile Insurance Company | Methods of providing insurance savings based upon telematics and insurance incentives |
US20210118249A1 (en) | 2014-11-13 | 2021-04-22 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle salvage and repair |
AU2016286112B2 (en) * | 2015-06-30 | 2023-02-16 | Northwest Biotherapeutics, Inc. | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response |
WO2017002045A1 (en) | 2015-06-30 | 2017-01-05 | Stemlab, Sa | A viable cell population, method for production and uses thereof |
US20210272207A1 (en) | 2015-08-28 | 2021-09-02 | State Farm Mutual Automobile Insurance Company | Vehicular driver profiles and discounts |
US11441916B1 (en) | 2016-01-22 | 2022-09-13 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle trip routing |
US10395332B1 (en) | 2016-01-22 | 2019-08-27 | State Farm Mutual Automobile Insurance Company | Coordinated autonomous vehicle automatic area scanning |
US11719545B2 (en) | 2016-01-22 | 2023-08-08 | Hyundai Motor Company | Autonomous vehicle component damage and salvage assessment |
US11242051B1 (en) | 2016-01-22 | 2022-02-08 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle action communications |
US10747234B1 (en) | 2016-01-22 | 2020-08-18 | State Farm Mutual Automobile Insurance Company | Method and system for enhancing the functionality of a vehicle |
US10134278B1 (en) | 2016-01-22 | 2018-11-20 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle application |
US10324463B1 (en) | 2016-01-22 | 2019-06-18 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation adjustment based upon route |
KR102038114B1 (ko) * | 2016-02-26 | 2019-10-30 | 주식회사 엘지화학 | 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물 |
WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5366866A (en) * | 1991-07-25 | 1994-11-22 | Duke University | Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB |
US5227471A (en) * | 1992-01-30 | 1993-07-13 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma |
US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
SK40898A3 (en) * | 1995-10-04 | 1999-04-13 | Immunex Corp | Use of flt3-ligand, vaccine adjuvants, expand media, a preparation and cells population and method |
US7659119B2 (en) * | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
EP0922758B1 (en) * | 1997-10-27 | 2009-04-15 | Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
JP2000143534A (ja) * | 1998-11-13 | 2000-05-23 | Asahi Chem Ind Co Ltd | 樹状細胞ワクチン及びその製造方法 |
JP2000279181A (ja) * | 1999-04-01 | 2000-10-10 | Japan Science & Technology Corp | ヒト樹状細胞の発現遺伝子群 |
US20030108527A1 (en) * | 1999-12-28 | 2003-06-12 | Tsukasa Seya | Maturation-promoting agent for immature dendrtic cells |
US6247378B1 (en) * | 2000-01-06 | 2001-06-19 | Deere & Company | Operator control device for an infinitely variable transmission |
AU2001259760B2 (en) * | 2000-05-12 | 2006-10-05 | Northwest Biotherapeutics, Inc. | Method to increase class I presentation of exogenous antigens by human dendritic cells |
JP2004520033A (ja) * | 2001-01-15 | 2004-07-08 | イ・デ・エム・イミュノ−デジネ・モレキュル | 分化拘束された成熟樹状細胞の調製用補助組成物 |
AU2002326463A1 (en) * | 2001-07-25 | 2003-02-17 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
-
2002
- 2002-09-06 ES ES02761594.7T patent/ES2598109T3/es not_active Expired - Lifetime
- 2002-09-06 DK DK02761594.7T patent/DK1441591T3/en active
- 2002-09-06 MX MXPA04002147A patent/MXPA04002147A/es active IP Right Grant
- 2002-09-06 US US10/488,744 patent/US20050059151A1/en not_active Abandoned
- 2002-09-06 IL IL16072002A patent/IL160720A0/xx unknown
- 2002-09-06 EP EP10181985.2A patent/EP2322603B1/en not_active Expired - Lifetime
- 2002-09-06 JP JP2003526345A patent/JP2005505270A/ja active Pending
- 2002-09-06 CN CN028198174A patent/CN1636229B/zh not_active Expired - Fee Related
- 2002-09-06 DK DK10181985.2T patent/DK2322603T3/da active
- 2002-09-06 BR BRPI0212545A patent/BRPI0212545B8/pt not_active IP Right Cessation
- 2002-09-06 ES ES10181985T patent/ES2766299T3/es not_active Expired - Lifetime
- 2002-09-06 KR KR1020117012621A patent/KR20110081341A/ko not_active Application Discontinuation
- 2002-09-06 EP EP19202820.7A patent/EP3653055A1/en not_active Withdrawn
- 2002-09-06 CN CN201210470111.XA patent/CN102973928B/zh not_active Expired - Fee Related
- 2002-09-06 KR KR1020047003386A patent/KR20050027163A/ko not_active Application Discontinuation
- 2002-09-06 PT PT2761594T patent/PT1441591T/pt unknown
- 2002-09-06 PL PL02372098A patent/PL372098A1/xx not_active Application Discontinuation
- 2002-09-06 WO PCT/US2002/028620 patent/WO2003022215A2/en active Application Filing
- 2002-09-06 PT PT101819852T patent/PT2322603T/pt unknown
- 2002-09-06 CA CA2459713A patent/CA2459713C/en not_active Expired - Lifetime
- 2002-09-06 NZ NZ531530A patent/NZ531530A/en not_active IP Right Cessation
- 2002-09-06 KR KR1020147023675A patent/KR101803702B1/ko active IP Right Grant
- 2002-09-06 EP EP02761594.7A patent/EP1441591B1/en not_active Expired - Lifetime
-
2004
- 2004-03-03 IL IL160720A patent/IL160720A/en active IP Right Grant
- 2004-03-05 NO NO20040965A patent/NO338147B1/no not_active IP Right Cessation
-
2006
- 2006-01-04 HK HK06100064.5A patent/HK1079989A1/xx not_active IP Right Cessation
-
2008
- 2008-05-29 US US12/129,549 patent/US20080254064A1/en not_active Abandoned
- 2008-09-19 AU AU2008221592A patent/AU2008221592B2/en not_active Ceased
-
2011
- 2011-07-04 JP JP2011148711A patent/JP5777956B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-18 IL IL219266A patent/IL219266A/en active IP Right Grant
-
2015
- 2015-03-02 JP JP2015040165A patent/JP6114768B2/ja not_active Expired - Fee Related
- 2015-11-16 NO NO20151562A patent/NO20151562A1/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL219266A0 (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response | |
AU2003253897A8 (en) | Dendritic cell pontentiation | |
AU2002318944A1 (en) | Methods and compositions relating to plasmacytoid dendritic cells | |
IL159578A (en) | Differentiated cell population for generating osteoprogenitors or osteoblasts | |
EP1551372B8 (en) | Sequestering subunit and related compositions and methods | |
AU2002249531A1 (en) | Immunotherapy based on dendritic cells | |
AU2008243079A1 (en) | Compositions and methods for generating an immune response | |
EP1447092A4 (en) | METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS | |
AU2001283240A1 (en) | High expansion dental alloys | |
AU2003297595A8 (en) | Atm kinase compositions and methods | |
GB0319495D0 (en) | An implant | |
AU2002305452A1 (en) | Regulating immine responses using dendritic cells | |
AU2002228932A1 (en) | Maturation of dendritic cells | |
AU2002365938A8 (en) | Modified antigen-presenting cells | |
AU2003278407A1 (en) | Sustained release compositions containing alfuzosin | |
EP1411897A4 (en) | COMPOSITIONS AND METHODS FOR INTRA-CELLULAR DELIVERY | |
AU2003214985A1 (en) | Polymerized wax candles | |
AU2001283226A1 (en) | Methods and compositions for inhibiting rad51 | |
EP1283727A4 (en) | COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF DENDRITIC CELLS | |
AU2002365136A8 (en) | Compositions and methods for controlled release | |
AU2002336522A1 (en) | Compositions and methods for t cell priming and immunotherapy | |
GB0305560D0 (en) | Fuel formulations | |
AU2002241930A1 (en) | Methods and compositions for extracting proteins from cells | |
AU2002330915A1 (en) | Gravity electrical generating system | |
AUPS224002A0 (en) | Graft (gravity) engine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210910 |